The Novogen Limited (NVGN) Receiving Somewhat Favorable News Coverage, Report Shows

The Novogen Limited (NVGN) Receiving Somewhat Favorable News Coverage, Report Shows

A number of equities analysts have recently weighed in on NVGN shares. Zacks Investment Research raised Novogen Limited from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Friday, March 3rd. HC Wainwright set a $5.00 price target on Novogen Limited and gave the company a “buy” rating in a research note on Tuesday, February 28th.

News headlines about Novogen Limited (NASDAQ:NVGN) have been trending somewhat positive this week, AlphaOne Sentiment reports. The research firm, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novogen Limited earned a news sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also gave press coverage about the biotechnology company an impact score of 25 out of 100, indicating that recent press coverage is very unlikely to have an effect on the stock’s share price in the next few days.

About Novogen Limited Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NVGN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Novogen Limited Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novogen Limited and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment